Core Viewpoint - 九州通's medical device segment showed strong growth in the first three quarters of 2025, with sales revenue reaching 28.963 billion yuan, a year-on-year increase of 17.20% [1] Group 1: Business Performance - The medical device business covers three main areas: OTC, medical, and professional services, demonstrating a diversified and collaborative development pattern [1] - In the OTC segment, 九州通 collaborated with well-known brands such as Yuyue, Sanor, Kefu Mei, and Durex, achieving comprehensive coverage across all categories and channels [1] - The online business saw significant growth due to the "old-for-new" policy for consumer goods, with related sales exceeding 537 million yuan in the first three quarters [1] Group 2: Medical Business - 九州通 focuses on high-value consumables in major surgical, vascular intervention, orthopedics, and IVD fields, establishing partnerships with over 60% of the global top 100 multinational companies and 80% of domestic top 100 industrial enterprises [1] - The sales revenue from medical equipment under the "old-for-new" policy reached 5 billion yuan, marking a 42% year-on-year increase [1] - The company accelerated the expansion of its SPD (Supply Processing Distribution) business, signing 28 new projects in the first three quarters, with a cumulative total of 132 bids won [1] Group 3: Professional Services - 九州通 continues to optimize its SPD system and digital service platforms such as the Orthopedic Chang'e platform, advancing the development of SPD smart cabinets [1] - The company achieved full tracking of personnel and goods in 3D trajectories, providing integrated supply chain solutions for hospitals [1]

Core Insights - The company, Jiuzhoutong, held its Q3 2025 earnings presentation on November 4, showcasing advancements in digitalization and AI technology applications [1] Group 1: Financial Performance - In the first three quarters of 2025, the company's R&D investment reached 229 million yuan, with the number of R&D personnel increasing to 1,591 [1] Group 2: Technological Advancements - Jiuzhoutong has developed an AI intelligent system covering multiple business scenarios through independent R&D and partnerships with companies like Alibaba Cloud and Tencent Cloud [1] - The company has created several intelligent platforms, including AI+Smart Logistics, AI+Traditional Chinese and Western Medicine Diagnosis, and AI+Medical Devices [1] Group 3: Business Applications - The orthopedic Chang'e platform and Jiuyi AI-assisted diagnosis system have significantly improved efficiency in surgical instrument inventory and disease diagnosis by integrating AI technology [1] - The smart logistics system employs intelligent scheduling algorithms, enhancing the "goods-to-person" picking efficiency by 10% [1] - Jiuyi AI-assisted diagnosis platform and the internal office system "Zhi Jiugo" have integrated the DeepSeek model, while Alibaba's "Tongyi Lingma" is applied in the R&D system, effectively shortening development time and enhancing operational and decision-making efficiency [1]